IOL Chemicals and Pharmaceuticals Limited (IOLCP.NS)
INR 434.5
(7.04%)
INR 434.5
(7.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.32 Billion INR | 23.03% |
| 2022 | 5.14 Billion INR | -9.72% |
| 2021 | 5.69 Billion INR | 62.96% |
| 2020 | 3.49 Billion INR | -3.41% |
| 2019 | 3.62 Billion INR | -22.57% |
| 2018 | 4.67 Billion INR | -22.84% |
| 2017 | 6.05 Billion INR | -3.63% |
| 2016 | 6.28 Billion INR | 6.43% |
| 2015 | 5.9 Billion INR | 19.48% |
| 2014 | 4.94 Billion INR | -7.04% |
| 2013 | 5.31 Billion INR | -3.98% |
| 2012 | 5.53 Billion INR | 7.9% |
| 2011 | 5.13 Billion INR | 17.33% |
| 2010 | 4.37 Billion INR | 21.52% |
| 2009 | 3.6 Billion INR | 22.39% |
| 2008 | 2.94 Billion INR | 88.13% |
| 2007 | 1.56 Billion INR | 8.78% |
| 2006 | 1.43 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -16.11 Billion INR | -354.63% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 6.32 Billion INR | 13.02% |
| 2023 FY | 6.32 Billion INR | 23.03% |
| 2023 Q2 | 4.91 Billion INR | 0.0% |
| 2023 Q3 | 5.6 Billion INR | 13.9% |
| 2022 FY | 5.14 Billion INR | -9.72% |
| 2022 Q4 | 5.14 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 5.68 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 5.69 Billion INR | 62.96% |
| 2021 Q4 | 5.69 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 4.18 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 3.49 Billion INR | -3.41% |
| 2020 Q4 | 3.49 Billion INR | 0.0% |
| 2020 Q2 | 3.58 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q4 | 3.62 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 3.8 Billion INR | 0.0% |
| 2019 FY | 3.62 Billion INR | -22.57% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 4.67 Billion INR | 0.0% |
| 2018 Q2 | 5.65 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 4.67 Billion INR | -22.84% |
| 2017 Q2 | 6.37 Billion INR | 0.0% |
| 2017 FY | 6.05 Billion INR | -3.63% |
| 2017 Q4 | 6.05 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 6.04 Billion INR | 0.0% |
| 2016 Q4 | 6.28 Billion INR | 0.0% |
| 2016 FY | 6.28 Billion INR | 6.43% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 5.9 Billion INR | 19.48% |
| 2015 Q2 | 5.8 Billion INR | 0.0% |
| 2015 Q4 | 5.9 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 5.29 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 4.94 Billion INR | 0.0% |
| 2014 FY | 4.94 Billion INR | -7.04% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 5.58 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 5.31 Billion INR | 0.0% |
| 2013 FY | 5.31 Billion INR | -3.98% |
| 2012 FY | 5.53 Billion INR | 7.9% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 10.79 Billion INR | 0.0% |
| 2012 Q4 | 5.53 Billion INR | 0.0% |
| 2011 FY | 5.13 Billion INR | 17.33% |
| 2010 FY | 4.37 Billion INR | 21.52% |
| 2009 FY | 3.6 Billion INR | 22.39% |
| 2008 FY | 2.94 Billion INR | 88.13% |
| 2007 FY | 1.56 Billion INR | 8.78% |
| 2006 FY | 1.43 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sigachi Industries Limited | 2.53 Billion INR | -150.029% |
| Ind-Swift Limited | 13.45 Billion INR | 52.955% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -30.019% |
| Sakar Healthcare Limited | 1.26 Billion INR | -400.989% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 95.842% |
| Innova Captab Limited | 4.89 Billion INR | -29.165% |
| Divi's Laboratories Limited | 18.99 Billion INR | 66.672% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -72.868% |
| Morepen Laboratories Limited | 4.45 Billion INR | -41.91% |
| Mankind Pharma Limited | 23.87 Billion INR | 73.491% |
| Sequent Scientific Limited | 8.27 Billion INR | 23.511% |
| Wanbury Limited | 3.15 Billion INR | -100.566% |
| Laurus Labs Limited | 42.71 Billion INR | 85.183% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 43.583% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -22.158% |
| Alembic Limited | 1.43 Billion INR | -341.931% |
| Hikal Limited | 12.99 Billion INR | 51.297% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 61.11% |
| Neuland Laboratories Limited | 5.49 Billion INR | -15.101% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 40.896% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 90.28% |
| Themis Medicare Limited | 1.88 Billion INR | -235.304% |
| RPG Life Sciences Limited | 1.38 Billion INR | -358.549% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 91.184% |
| Lupin Limited | 96.23 Billion INR | 93.424% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -707.439% |
| Wockhardt Limited | 39.87 Billion INR | 84.126% |
| Vaishali Pharma Limited | 371.16 Million INR | -1605.154% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 23.293% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -2032.666% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 89.671% |
| FDC Limited | 3.7 Billion INR | -70.627% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 94.083% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -882.927% |
| Eris Lifesciences Limited | 38.26 Billion INR | 83.462% |
| Venus Remedies Limited | 1.39 Billion INR | -354.401% |
| ZIM Laboratories Limited | 2.08 Billion INR | -204.163% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -200.111% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -3860.736% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -80.537% |
| Shilpa Medicare Limited | 12.93 Billion INR | 51.062% |
| Albert David Limited | 1.15 Billion INR | -450.289% |
| Ajanta Pharma Limited | 10.71 Billion INR | 40.908% |
| Hester Biosciences Limited | 3.59 Billion INR | -76.061% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -211.12% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 55.088% |
| Gufic Biosciences Limited | 5.59 Billion INR | -13.02% |
| Windlas Biotech Limited | 1.76 Billion INR | -259.046% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -147.107% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -267.492% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -220.238% |
| Granules India Limited | 22.95 Billion INR | 72.428% |
| Aarti Drugs Limited | 11.5 Billion INR | 44.985% |
| Bal Pharma Limited | 2.51 Billion INR | -152.019% |
| Alkem Laboratories Limited | 48.6 Billion INR | 86.979% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 96.552% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -488.984% |
| Medicamen Biotech Limited | 940.36 Million INR | -573.024% |
| Unichem Laboratories Limited | 8.06 Billion INR | 21.568% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -870.275% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -2091.455% |
| Valiant Laboratories Limited | 1.05 Billion INR | -498.047% |
| Orchid Pharma Limited | 3.84 Billion INR | -64.64% |
| Medico Remedies Limited | 438.24 Million INR | -1344.15% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -176.436% |
| Ipca Laboratories Limited | 33.74 Billion INR | 81.244% |
| Brooks Laboratories Limited | 248.6 Million INR | -2445.806% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -443.155% |
| Piramal Enterprises Limited | 560.47 Billion INR | 98.871% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 92.287% |
| NATCO Pharma Limited | 10.53 Billion INR | 39.908% |
| Suven Life Sciences Limited | 148.62 Million INR | -4158.416% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -112.814% |
| Strides Pharma Science Limited | 37.68 Billion INR | 83.204% |
| Indoco Remedies Limited | 10.34 Billion INR | 38.806% |
| Alpa Laboratories Limited | 307.12 Million INR | -1960.712% |
| Lasa Supergenerics Limited | 541.92 Million INR | -1067.855% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -62.575% |